Insurance Coverage for GLP-1 Drugs in 2026: What Changed

Insurance coverage for weight loss medications has always been complicated in the United States. Medicare did not cover GLP-1 drugs for obesity alone until late 2024, when a policy shift opened the door for broader coverage. Now in 2026, the landscape looks different in several important ways. If you have been trying to get your plan to cover semaglutide, tirzepatide, or similar medications, here is what you need to know.

Medicare and the shift that happened

For years, Medicare Part D excluded coverage of weight loss drugs. That changed with the Treat and Reduce Obesity Act being implemented in phases. As of mid-2025, Medicare Advantage plans began covering GLP-1 receptor agonists for beneficiaries with a BMI of 30 or higher, or 27 with a weight-related comorbidity. This was a significant shift.

Private insurers followed, though at different speeds. Some covered immediately, others waited to see how the legal landscape settled. By 2026, the majority of large employer-sponsored plans offer some level of coverage, but the details vary wildly from one plan to the next.

What changed in 2026 specifically

The biggest change in 2026 is not legislative, it is operational. Insurance companies have gotten better at processing GLP-1 coverage requests. The wild variation in approval criteria between carriers has narrowed somewhat. Where one insurer required a 12-month diet history and another required none, things are starting to standardize around a smaller set of accepted criteria.

Prior authorization requirements remain in place for most plans. Your doctor will need to submit a prior authorization form documenting medical necessity. This typically includes your current BMI, any weight-related health conditions like type 2 diabetes or hypertension, and confirmation that lifestyle interventions have been tried.

One new development is that some insurers now accept telehealth prescriptions for the initial authorization, as long as there is an established doctor-patient relationship. That removed a barrier for people in areas without easy access to specialists.

Common reasons for denial and what to do about them

The most common denial reasons have not changed much. Lack of medical necessity documentation tops the list. If the prior authorization does not clearly explain why this specific medication is appropriate for your situation, it gets denied. Insurance companies process thousands of these requests. The ones with thorough documentation get approved more often.

Another common reason is step therapy. Some plans require you to try older, cheaper medications before moving to a GLP-1. If your doctor prescribed Ozempic but your plan wants you to try metformin first, that is a step therapy requirement. You or your doctor can sometimes request an exception if there is a medical reason to skip that step.

Formulary exclusions also cause problems. Not every plan covers every GLP-1. Wegovy and Zepbound may be covered while Saxenda is not, or vice versa. Check your formulary carefully and ask your doctor about alternatives if your specific medication is excluded.

If you get denied, appeal. The first appeal is usually internal to the insurance company. If that fails, there is an external appeal reviewed by an independent third party. Many people skip the appeal process because it feels overwhelming, but studies show a significant percentage of appeals are successful.

Practical steps to take right now

Start by calling the member services number on your insurance card and asking specifically about GLP-1 coverage for obesity. Get the name of the person you spoke with and take notes. Ask what prior authorization form your doctor needs to complete and what criteria they use to approve.

Then have a conversation with your doctor. Bring your insurance information and ask if their staff has experience filing GLP-1 prior authorizations. Offices that handle this regularly know exactly what language the insurance company wants to see and can submit cleaner requests.

Keep records of everything. Every phone call, every document submitted, every denial letter. If you need to escalate to an external appeal or legal action, that paper trail is your evidence.

For a personalized starting point on understanding your options and next steps, you can take a short quiz at Ozempro that helps map out your situation and points you toward relevant resources.

The bottom line is that coverage is more accessible than it was two years ago, but it still requires persistence. Do not take the first no as final. Learn the process, document everything, and appeal when necessary. Your health is worth the effort.

---

Image: medical documents and insurance card on a desk with laptop

References

• EMA — Mounjaro (tirzepatida), EPAR
• Jastreboff et al., SURMOUNT-1 — NEJM (2022)
• OMS — Obesity and overweight, fact sheet